These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21154521)

  • 21. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discounting and risk characteristics in clinical decision-making.
    Ortendahl M; Fries JF
    Med Sci Monit; 2006 Mar; 12(3):RA41-5. PubMed ID: 16501432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discounting in economic evaluations: stepping forward towards optimal decision rules.
    Gravelle H; Brouwer W; Niessen L; Postma M; Rutten F
    Health Econ; 2007 Mar; 16(3):307-17. PubMed ID: 17006970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Framing health messages based on anomalies in time preference.
    Ortendahl M; Fries JF
    Med Sci Monit; 2005 Aug; 11(8):RA253-6. PubMed ID: 16049392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discounting in decision making: the consistency argument revisited empirically.
    Brouwer WB; van Exel NJ
    Health Policy; 2004 Feb; 67(2):187-94. PubMed ID: 14720636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
    Jit M; Mibei W
    Vaccine; 2015 Jul; 33(32):3788-94. PubMed ID: 26144897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Economic evaluation and decision-making in health. The role of economic evaluation in the adoption and spread of health technologies. 2008 SESPAS Report].
    Oliva J; Antoñanzas F; Rivero-Arias O
    Gac Sanit; 2008 Apr; 22 Suppl 1():137-42. PubMed ID: 18405563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spanish recommendations on economic evaluation of health technologies.
    López-Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
    Eur J Health Econ; 2010 Oct; 11(5):513-20. PubMed ID: 20405159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decision makers' views on health care objectives and budget constraints: results from a pilot study.
    Al MJ; Feenstra T; Brouwer WB
    Health Policy; 2004 Oct; 70(1):33-48. PubMed ID: 15312708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts.
    O'Mahony JF; de Kok IM; van Rosmalen J; Habbema JD; Brouwer W; van Ballegooijen M
    Value Health; 2011 Jun; 14(4):438-42. PubMed ID: 21669368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed.
    Basu A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):163-5. PubMed ID: 23570425
    [No Abstract]   [Full Text] [Related]  

  • 36. Case-studies of displacement effects in Dutch hospital care.
    Wammes JJG; Frederix G; Govaert P; Determann D; Evers S; Paulus A; Stadhouders N; Jeurissen P; Oortwijn W; Adang EMM
    BMC Health Serv Res; 2020 Mar; 20(1):263. PubMed ID: 32228590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of the decisions of the Israeli Public Committee for updating the National List of Health Services in 2006/2007.
    Shmueli A
    Value Health; 2009; 12(2):202-6. PubMed ID: 18657095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of funding recommendations for health technologies at the state level: A South Australian case study.
    Lambert R; Carter D; Burgess N; Haji Ali Afzali H
    Int J Health Plann Manage; 2018 Oct; 33(4):806-822. PubMed ID: 29676055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Year 2006 update of the Israel National List of Health Services.
    Tamir O; Rabinovich M; Shani M
    Isr Med Assoc J; 2006 Sep; 8(9):595-600. PubMed ID: 17058406
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.